Clinical trial
A Phase II Clinical Study of the Efficacy and Safety of Preoperative Sintilimab in Combination With Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Carcinoma
NCT04548440 is registered in ClinicalTrials.gov with Sun Yat-Sen University Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Clinical Study of the Efficacy and Safety of Preoperative Sintilimab in Combination With Nab-paclitaxel and Cisplatin in Borderline Resectable Esophageal Squamous Carcinoma
- Lead sponsor
- Sun Yat-Sen University Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2020
- Completion date
- December 31, 2022
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.